These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26970503)

  • 1. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
    Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A
    Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
    Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS
    Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of the effects of carbocysteine lysine salt on frequency of exacerbations in COPD patients treated with or without inhaled steroids.
    Paone G; Lanata L; Saibene F; Toti S; Palermo P; Graziani C; Flore MC; Ramaccia M; Puglisi G
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6727-6735. PubMed ID: 31378916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.
    Hooper C; Calvert J
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):659-69. PubMed ID: 19281081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis.
    Zeng Z; Yang D; Huang X; Xiao Z
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2277-2283. PubMed ID: 28814855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of carbocisteine in the treatment of chronic obstructive pulmonary disease and impact on the quality of life.
    Alibašić E; Skopljak A; Čengić A; Krstović G; Trifunović N; Čatić T; Kapo B; Mehić M; Hadžimuratović A
    Med Glas (Zenica); 2017 Aug; 14(2):182-188. PubMed ID: 28786969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exacerbations of chronic obstructive pulmonary disease.
    Wedzicha JA; Donaldson GC
    Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease.
    Tatsumi K; Fukuchi Y;
    J Am Geriatr Soc; 2007 Nov; 55(11):1884-6. PubMed ID: 17979906
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of mucolytics in COPD: A Delphi consensus study.
    Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
    Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys).
    Carpagnano GE; Resta O; Foschino-Barbaro MP; Spanevello A; Stefano A; Di Gioia G; Serviddio G; Gramiccioni E
    Eur J Pharmacol; 2004 Nov; 505(1-3):169-75. PubMed ID: 15556150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
    Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
    COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbocisteine for acute exacerbations of COPD.
    Waller P; Suissa S
    Lancet; 2008 Nov; 372(9650):1630; author reply 1631-2. PubMed ID: 18994655
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
    Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
    Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbocisteine for acute exacerbations of COPD.
    Mohapatra PR; Aggarwal D
    Lancet; 2008 Nov; 372(9650):1630-1; author reply 1631-2. PubMed ID: 18994656
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
    Dal Negro RW; Visconti M; Turco P
    Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of carbocisteine on type A seasonal influenza virus infection in human airway epithelial cells.
    Yamaya M; Nishimura H; Shinya K; Hatachi Y; Sasaki T; Yasuda H; Yoshida M; Asada M; Fujino N; Suzuki T; Deng X; Kubo H; Nagatomi R
    Am J Physiol Lung Cell Mol Physiol; 2010 Aug; 299(2):L160-8. PubMed ID: 20543005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
    Moretti M; Fagnani S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study.
    Kuyucu T; Güçlü SZ; Saylan B; Demir C; Senol T; Güner S; Koyuncu E; Ozen F; Oztürk S; Cangül Z; Ağanoğlu S; Ozkaya S; Ocak SC; Akkurt H; Intepe YS; Bayrak MG; Güler T; Bekçi TT; Soyyiğit S; Seyfettin S; Kula O; Akbay MO; Büyükgöze B; Asal G; Başlilar S; Oztürk O;
    Tuberk Toraks; 2011; 59(4):328-39. PubMed ID: 22233302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.
    Bateman ED; Feldman C; O'Brien J; Plit M; Joubert JR;
    S Afr Med J; 2004 Jul; 94(7 Pt 2):559-75. PubMed ID: 15283307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.